Prostate Ewing sarcoma/peripheral primitive neuroectodermal tumor (ES/PNET) is extremely rare. Currently, a multimodal approach is recommended, although there is no standard treatment. Nevertheless, this tumor has a very poor prognosis, with the longest reported survival of 24 months. We present a case of locally advanced prostate ES/PNET in a 29-year-old male who was treated with a multimodal approach. The patient is alive and disease free, with a seven year follow-up, with very good quality of life. This exceptionally long survival may be the result of the very aggressive multimodal treatment chosen and described herein.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.urology.2021.05.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Quest for discovering novel CDK12 inhibitor.
J Recept Signal Transduct Res
December 2024
Department of Dravyaguna, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
CDK12 is essential for cellular processes like RNA processing, transcription, and cell cycle regulation, inhibiting cancer cell growth and facilitating macrophage invasion. CDK12 is a significant oncogenic factor in various cancers, including HER2-positive breast cancer, Anaplastic thyroid carcinoma, Hepatocellular carcinoma, prostate cancer, and Ewing sarcoma. It is also regarded as a potential biomarker, emphasizing its broader significance in oncology.
View Article and Find Full Text PDFAdvancing Anticancer Drug Discovery: Leveraging Metabolomics and Machine Learning for Mode of Action Prediction by Pattern Recognition.
Adv Sci (Weinh)
December 2024
Leibniz Institute of Plant Biochemistry, Dept. of Cell and Metabolic Biology, Weinberg 3, 06120, Halle (Saale), Germany.
Article Synopsis
- The development of new anti-cancer drugs is hindered by challenges in identifying their mode of action (MoA), but a combination of metabolomics and machine learning has been used to predict MoAs for new drug candidates targeting prostate cancer cells.
- In a study of 38 drugs affecting cancer metabolism, distinct metabolic patterns enabled accurate predictions of MoAs, and these predictions were validated across other cancer types such as breast cancer and Ewing's sarcoma, albeit with some loss in prediction quality.
- This approach not only enhances understanding of drug effects on cellular processes, such as mitochondrial dysfunction, but also opens up new avenues for optimizing drug combinations to improve treatment outcomes.
Menin in Cancer.
Genes (Basel)
September 2024
Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Article Synopsis
- Menin, a protein encoded by a specific gene, acts as a nuclear scaffold that regulates gene expression by interacting with chromatin modifiers and transcription factors.
- Its role in cancer is complex, as it can function as both a tumor suppressor in conditions like MEN1 syndrome and cholangiocarcinoma, and as a tumor promoter in various other cancers like leukemia and colorectal cancer, depending on the type and context of the tumor.
- The review focuses on the diverse roles of menin across different cancer types, emphasizing the need for further research to understand its mechanisms and therapeutic potential.
Safety, efficacy, and pharmacokinetics of oral testosterone undecanoate in males with hypogonadism.
Andrology
September 2024
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Background: Testosterone deficiency results from insufficient testosterone production. Testosterone therapy may require dose titration to reach eugonadal serum testosterone concentrations.
Objective: The primary objective was the efficacy of oral testosterone undecanoate (TLANDO; Antares Pharma Inc.
Immunohistochemical Evaluation of Schlafen 11 (SLFN11) Expression in Cancer in the Search of Biomarker-Informed Treatment Targets: A Study of 127 Entities Represented by 6658 Tumors.
Am J Surg Pathol
August 2024
Laboratory of Pathology, National Cancer Institute, Bethesda, MD.
Article Synopsis
- Schlafen 11 (SLFN11) is a helicase that regulates how cells respond to stress during DNA replication, and its expression can predict treatment outcomes in cancer patients receiving certain therapies.
- In a study involving 6,658 tumors, SLFN11 was found to be rare in common epithelial tumors (e.g., breast and prostate cancers) but prevalent in several more aggressive tumors and specific mesenchymal and neuroectodermal cancers.
- The absence of SLFN11 may lead to worse outcomes for patients treated with DNA-damaging drugs, suggesting the need for alternative treatments for those cancers that lack this biomarker.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!